Success for a third—and perhaps most important—covid-19 vaccine

  • 📰 TheEconomist
  • ⏱ Reading Time:
  • 57 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 26%
  • Publisher: 92%

United States Headlines News

United States Latest News,United States Headlines

If approved, AstraZeneca’s vaccine can be rolled out fast. It can be produced at many sites around the world, and 3bn doses can be made next year

IN JANUARY, when most of the world was just becoming aware of covid-19, scientists raced into their laboratories, clutching a freshly minted copy of the genetic code of the coronavirus that causes the disease. In those early days it was almost impossible to imagine that within 11 months three effective vaccines against covid-19 would be created. Yet this is exactly what has come to pass. For the third Monday running, the developers of a vaccine have announced highly encouraging results.

The trial also included a dosing regime in which some participants were initially given only a half-dose of the vaccine, followed by a full one. The efficacy of this regime reached 90%. Why might a lower initial dose yield a stronger response? The answer may lay in the method that the vaccine uses to deliver genetic material from the coronavirus into the body: in a viral vector—another virus, acting as a sort of envelope.

As with data on all three vaccines with results so far, much of the information provided is frustratingly preliminary. However, the academics at Oxford say they hope to submit a paper to a journal in the next 24 hours. It is not clear when the teams developing the other two vaccines will do the same.

Whatever the outcome of more thorough analyses, it is clear that the world has three highly effective vaccines. If approved, AstraZeneca’s can be rolled out fast. It can be produced at many sites around the world, and 3bn doses can be made next year . Pascal Soriot, head of AstraZeneca, said his firm has partnerships with suppliers in India, Latin America, Russia and Thailand.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Of course it’s cheaper at 70% effective that then magically became 90% effective, how much did they pay you for this propaganda?

Cheaper doesn’t always mean better

Pharma all alike - all vying for a piece of the money pie based on repetitive human suffering. They are not here to help. They are here to make money from suffering

You do not Tell here that the New World Order tells you what to do. What is the cure for a HOAX ❓

Will Princ e Charle s be vaccinated too? 😳

95% only bad news(

As per WHO's there were 21 vaccines under trials all over d world. Interestingly bulk producon of many vacines will be done by Indian Cos. India will buy ₹250/- a dose. Hopefully, GOI will give it free of cost. Why nt ? GOI hd writenoff loan to big Cos in billions& billions

With 70% efficiency as of yesterday, i don't think so

The 3rd vaccine by AstraZeneca May be the charm. It's cheaper, can be stored easily & prelim data indicates it may stop transmission. It sounds like a winner & no-brainer. Of course the real Rosetta Stone will be a vaccine that's 1 & done. Just like the flu vaccine. Once is it!

Nice work. Remembering those lost to this virus. 👍🏼😷

vaccinations aren't about health... they are about money... and power... perpetual sicknesses is perpetual money and power... don't be stupid... don't be cattle... don't be muzzled sheep... don't play into their perpetual sickness... tell them to get bent... just say no loud(:~:)

Manufacturing consent.

👏👏👏

Big rally of christmas. Índices up . Who take this . Jp Morgan and goldman. Big manipulator

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 6. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.